NCT01932242View on ClinicalTrials.gov

Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 23, 2013

Primary Completion Date

April 19, 2014

Study Completion Date

April 19, 2014

Conditions
Inhalational Anthrax
Interventions
BIOLOGICAL

ETI-204

Monoclonal Antibody

OTHER

Placebo

Placebo for ETI-204

Trial Locations (2)

55404

DaVita, Minneapolis

66211

Quintiles, Overland Park

Sponsors
All Listed Sponsors
lead

Elusys Therapeutics

OTHER

NCT01932242 - Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers | Biotech Hunter | Biotech Hunter